A61K 40/4265
Alpha-feto protein
Official title: {Alpha-feto protein}
A61K40/4265 (Alpha-feto protein) appears on 25 US grants and 50 published applications in this corpus.
Search patents in A61K- Granted patents
- 25
- Published applications
- 50
- Assignees
- 22
- Inventors
- 87
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 2 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 2 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 3 | 4 |
| 2019 | 2 | 4 |
| 2020 | 2 | 3 |
| 2021 | 3 | 11 |
| 2022 | 2 | 9 |
| 2023 | 2 | 6 |
| 2024 | 5 | 2 |
| 2025 | 1 | 5 |
| 2026 | 3 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Presenting cell and use thereof in cell therapy11 Aug 2026US 12,702,708 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Kits and methods for determining copy number of mouse TCR gene17 Mar 2026US 12,577,614 B2Shanghai AbelZeta Ltd.
- High-affinity TCR for recognizing AFP antigen10 Mar 2026US 12,570,713 B2Xlifesc, Ltd.
- Constructs specifically recognizing Glypican 3 and uses thereof25 Nov 2025US 12,479,924 B2Eureka Therapeutics, Inc.
- Human alpha fetoprotein-specific t cell receptors and uses thereof24 Dec 2024US 12,173,045 B2Augusta University Research Institute, Inc.
- Antibody/t-cell receptor chimeric constructs and uses thereof27 Nov 2025US 2025/0361286 A1Eureka Therapeutics, Inc.
- D-domain containing polypeptides and uses thereof20 Nov 2025US 2025/0353908 A1Arcellx, Inc.
- T cell receptors17 Apr 2025US 2025/0122263 A1Adaptimmune Limited
- T Cell Modification and Use Thereof6 Feb 2025US 2025/0043011 A1Adaptimmune Limited
- Multifunctional immune cell therapies23 Jan 2025US 2025/0026849 A1Arcellx, Inc.
Most cited
By later US patents
- Method and compositions for treating hepatocellular cancer33US 7,098,306 B2The Regents of the University of California · 2006
- Antibody/T-cell receptor chimeric constructs and uses thereof16US 10,464,988 B2Eureka Therapeutics, Inc. · 2019
- Antibody/T-cell receptor chimeric constructs and uses thereof15US 10,098,951 B2Eureka Therapeutics, Inc. · 2018
- Constructs targeting AFP peptide/MHC complexes and uses thereof12US 10,011,658 B2Eureka Therapeutics, Inc. · 2018
- Antibody/T-cell receptor chimeric constructs and uses thereof8US 10,822,389 B2Eureka Therapeutics, Inc. · 2020